Joint Formulary & PAD

Calcium acetate - Hyperphosphataemia

You are here : Home > Formulary Search > Calcium acetate - Hyperphosphataemia

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
SPC
Restrictions / Comments :
Important

To be used for hyperphosphataemia associated with pemigatinib used in accordance with the SACT protocol

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Calcium acetate
Indication :
Hyperphosphataemia
Group Name :
Keywords :
Brand Names Include :
Renacet
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Committee Recommendations (1)

05 Feb 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

This drug has been included on the joint formulary having been agreed by the DTC of at least one Surrey Heartlands Acute Trust.

See “Formulary Status” to identify where this drug has been agreed for use.

Other Indications

Below are listed other indications that Calcium acetate is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Hyperphosphataemia.

  • No records returned.